We recently reported that alpha 2A -adrenoceptor (AR) desensitization and down-regulation occurs after 24h treatment with EPI (0.3 µM) in BE(2)-C cells that express both alpha 2 -and beta 2 -ARs (Bawa et al., 2003). The same concentration of NE has no effect. The effect of EPI is prevented by beta 2 -AR blockade and is associated with an increase in GRK3 expression. Since differences in agonist-induced down-regulation of the alpha 2A -vs. alpha 2B -ARs have been reported, the present study examines the effects of simultaneous activation of alpha 2B -and beta 2 -ARs on alpha 2B -AR number and signaling. We studied NG108 cells that naturally express alpha 2B -ARs, and BN17 cells, NG108 cells transfected to express the human beta 2 -AR. In NG108 cells, alpha 2B -AR desensitization and down-regulation require treatment with 20 µM EPI or NE; GRK expression was not changed. In BN17 cells expressing beta 2 -ARs, the threshold EPI concentration for alpha 2B -AR desensitization and down-regulation was reduced to 0.3 µM; 10 µM NE was required for the same effect. Further, 24h EPI or NE treatments that produced desensitization also resulted in a selective 2-fold up-regulation of GRK3; GRK2 was unchanged. The beta-AR antagonist alprenolol (1 µM) and GRK3 antisense (but not sense) DNA, blocked 0.3 µM EPI-and 10 µM NE-induced desensitization and down-regulation of the alpha 2B -AR as well as GRK3 up-regulation.
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MATERIAL AND METHODS
Material:
The following drugs were purchased from the indicated sources:
(-) Epinephrine bitartarate (EPI), (+) isoproterenol bitartarate, phenylmethylsulphonylflouride (PMSF), alprenolol hydrochloride, phentolamine, cyclic adenosine 3', 5' monophosphate (cAMP), prostaglandin E1 (PGE 1 ), Dulbecco's modified Eagle's medium (DMEM), alprenolol hydrochloride, adrenal cortex extract, hydroxyapatite, HAT supplement (0.1 mM hypoxanthine, 0.4 µM aminopterin, 16 µM thymidine), sodium orthovanadate, sodium pyrophosphate, pepstatin, leupeptin, aprotinin, isobutylmethylxanthine (IBMX) and poly-l-lysine hydrobromide, (Sigma Chemical Co., St.Louis, MO), (-) norepinephrine (NE) (RBI, Natick, MA), [ ) on PGE 1 -induced cAMP accumulation, intact cells were first incubated for 10 min at 37°C in HBSS buffer. Then PGE 1 (10 nM), NE and cells were added to assay tubes and the tubes were incubated for an additional 10 min at 37°C. In all the experiments, the β-AR antagonist alprenolol (1 µM) also was included in this step. All assays were performed in duplicate in a total volume of 0.5 ml. The assay was terminated by removing the tubes to a boiling water bath for 5 min. After boiling, samples were centrifuged for 5 min at 14,000Xg, and cAMP levels from the supernatant fractions were determined in a [ 3 H] cAMP (0.8 pmol) binding assay as previously described (Standifer et al., 1994) . Preferential alpha 2 -adrenoceptor agonists were not used in this study because NG108 cells express imidazole receptors, the activation of which inhibits cAMP accumulation (Greney et al., 2000) . Since all preferential alpha 2 -adrenoceptor agonists would activate both alpha 2 and imidazole receptors in NG108 cells, this would significantly complicate any data interpretation.
Membrane preparation for receptor binding:
To prepare membranes for receptor binding, the cells were first washed 3 times with PBS (pH-7.4) and then harvested from the plates by gentle scraping. The cells were sedimented by centrifugation at 3000Xg for 10 minutes. The cell pellet was then suspended in 10 volumes of Tris-HCl buffer (50 mM, pH 7.7) containing NaCl (100 mM), Na 2 EDTA (10 mM) and PMSF (0.1 mM) and homogenized with a polytron homogenizer (setting 5, 10 sec). The membranes were incubated for 15 min at 25°C and sedimented by centrifugation (20,000 rpm) for 30 min at 4°C. The membranes were immediately used for the binding assay.
Radioligand binding assay to determine receptor number:
The α 2B -AR binding was performed with the α 2 -AR antagonist, [ mM, pH 7.4) at 23°C for 30 min. Assays were performed in triplicate and non-specific binding was defined using 100 µM phentolamine. At the end of the incubation period, reaction was terminated by adding Tris-HCl buffer (50 mM, pH 8.0 at 4°C) and filtration over Whatman GF/B paper (Brandel). The filter paper was washed thrice with 3-4 ml of the filtration buffer (50 mM Tris-HCl, pH 8.0, 4°C). The amount of radioactivity in the sample was determined by scintillation spectroscopy in a Beckman LS6000 liquid scintillation counter.
Western blot analysis:
Some of the cells collected either for the α 2B -AR response assay or receptor binding were used to prepare samples for Western blot analysis. Cell pellets were washed once with 1X PBS buffer (pH 7.4), lysed immediately in 100-150 µl of lysis buffer (50 mM Tris-HCl pH 8.0, 150 mM NaCl, 2 mM EDTA, 1% Triton-X 100, 0.1% SDS, 0.02% sodium azide, 100 µg/ml phenylmethylsulfonyl fluoride, 1 µg/ml leupeptin, 1 µg/ml aprotinin and 1 µg/ml pepstatin), vortexed and digested for 30 min in an ice-bath. The resultant cell lysate was diluted with 2X
Laemmli gel loading buffer (50 mM Tris-HCl, pH 6.8, 10% glycerol, 2% SDS, 0.1 mg/ml bromophenol blue). The proteins in the cell lysate were separated by SDS-polyacrylamide gel electrophoresis on a 10% polyacrylamide gel. The separated proteins were electrophoretically transferred to a PVDF membrane (Amersham Pharmacia Biotech, Buckinghamshire, England) using a Bio-Rad Mini Trans-Blot transfer gel unit. The PVDF membrane was then incubated for 1 h in Tris buffered saline, pH 7.6 (TBS-T; 20 mM Tris-HCl, 137 mM NaCl and 0.1% containing 5% nonfat milk protein. After removal of blocking buffer, the membrane were washed with TBS-T and incubated overnight at 4°C with rabbit polyclonal antisera (primary antibody) directed against, either G i2α (1:1000; Upstate Biotechnology, NY), GRK2 or GRK3 (1:1000; Santa Cruz Biotechnology, CA) in 2.5% non-fat milk. The blots were then washed with TBS-T to remove This article has not been copyedited and formatted. The final version may differ from this version. 
Results
In NG108 cells that express only alpha 2B -ARs, 24 h pretreatment with 20 µM NE was required to desensitize the alpha 2 -AR mediated inhibition of cAMP accumulation (figure 1A); 10 µM NE was insufficient to produce desensitization of the alpha 2B -ARs. Similarly, 20 µM but not 10 µM, EPI produced alpha 2 -adrenoceptor desensitization (figure 1B). Neither NE nor EPI, at concentrations that resulted in alpha 2 -adrenoceptor desensitization, produced any changes in the cellular expression of GRK2 or GRK3 (figure 2). However the desensitization was accompanied by down-regulation of specific alpha 2B -AR binding ( figure 3 ).
In BN17 cells that express both alpha 2B -and beta 2 -ARs, 24 h pretreatment with only 0.3 µM EPI resulted in desensitization of the alpha 2B -ARs (figure 4). This concentration was 67-fold lower than the minimal concentration of EPI that resulted in alpha 2B -AR desensitization in NG108 cells.
Pretreatment with 0.1 µM EPI had no significant effect on alpha 2B -AR responsiveness. Also in BN17 cells, the concentration of NE (10 µM NE) required to desensitize the alpha 2B -AR (figure 5) was reduced by only 2-fold as compared to the NG108 cells. More importantly, the effect of EPI or NE on alpha 2B -AR response was antagonized by the presence of the beta-AR antagonist alprenolol
(1 µM) during the EPI pretreatment (figure 6).
In addition to desensitization of the alpha 2B -AR, pretreatment of BN17 cells with 0.3 µM EPI also resulted in down-regulation of the alpha 2B -ARs that was dependent on co-activation of the alpha 2B -and the beta 2 -AR ( figure 7A ). The pretreatment did not change the affinity of [cells with 10 µM NE resulted in a beta 2 -AR dependent down-regulation of the alpha 2B -AR ( figure   7B ).
The effects of EPI and NE pretreatments on cellular levels of GRK3 also were different in BN17
cells, compared to NG108 cells. In BN17 cells, pretreatment with EPI or NE that resulted in alpha 2B -AR desensitization and down-regulation also produced a selective approximately 2-fold upregulation of GRK3 ( figure 8A ). This increase in GRK3 expression also was prevented when the pretreatment was done in the presence of 1 µM alprenolol ( figure 8A ). No effect on GRK2 expression was observed with either treatment (figure 8B).
Since desensitization and down-regulation of the alpha 2B -ARs in BN17 cells were accompanied by a selective up-regulation of GRK3 expression, and because all of these effects were prevented by beta-AR blockade with alprenolol, we determined if alpha 2B -AR desensitization and down- was sufficient to produce alpha 2B -AR desensitization by pretreating for 24 h with isoproterenol (1 µM). Isoproterenol pretreatment had no effect either on alpha 2B -AR responsiveness (figure 11A) or level ( figure 11B ) in BN17 cells, suggesting that simultaneous activation of the alpha 2B -and beta 2 -AR is necessary for alpha 2 -AR desensitization at lower agonist concentrations in BN17 cells.
Treating BN17 cells with 1 µM isoproterenol in the presence of 0.3 µM NE further tested this requirement of simultaneous activation of the alpha 2B -and beta 2 -AR. The NE and isoproterenol cotreatment desensitized ( figure 11A ) and down-regulated ( figure 11B ) the alpha 2B -AR. Also, pretreatment of the BN17 cells with 1 µM isoproterenol did not alter the cellular levels of either GRK2 or GRK3, but the co-treatment with 1 µM isoproterenol and 0.3 µM NE selectively increased the level of GRK3 (data not shown).
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Discussion
In the present study we demonstrate that simultaneous activation of the alpha 2B -and beta 2 -adrenoceptors results in down-regulation of the alpha 2B -adrenoceptor by EPI at concentrations ~70-fold lower than those required when the beta 2 -adrenoceptor is not activated. The mechanism responsible for this effect of EPI at lower agonist concentrations is a selective up-regulation of GRK3 expression that requires simultaneous alpha 2B -and beta 2 -adrenoceptor activation.
Prevention of GRK3 up-regulation by beta-adrenoceptor blockade or GRK3 antisense ODN treatment during the EPI pretreatment eliminates the alpha 2B -adrenoceptor down-regulation at low EPI concentrations (0.3 µM). Without simultaneous activation of both alpha 2B -and beta 2 -adrenoceptors, EPI and NE still produced alpha 2B -adrenoceptor down-regulation, but significantly higher agonists concentrations (20 µM) are required.
The results of this study reveal an intriguing difference between the threshold concentrations of the physiological agonists NE and EPI required to induce alpha 2B -adrenoceptor down-regulation.
This result is quite surprising in the context of the potency and efficacy of NE and EPI at the alpha 2 -adrenoceptor. It has repeatedly been reported that these agonists are equipotent and equiefficacious at this receptor (Jasper et al., 1998) . Therefore one would not expect the observed difference in the minimal concentration of EPI vs. NE required to induce down-regulation. However, the contribution of the beta 2 -adrenoceptor to this process immediately reveals the reason for this difference. In BN17 cells expressing both alpha 2B -and beta 2 -adrenoceptors, 0.3 µM EPI or 10 µM NE was the minimal concentration required to produce alpha 2B -adrenoceptor down-regulation, whereas in NG108 cells that express only the alpha 2B -adrenoceptor, the minimal concentration required to produce down-regulation was the same for NE or EPI, 20 µM. The present study also clearly defines the role of the beta 2 -adrenoceptor in the downregulation of the alpha 2B -adrenoceptor, i.e. to contribute to up-regulation of GRK3. However, it is important to recognize that neither alpha 2 -nor beta 2 -adrenoceptor activation alone produces GKR3 up-regulation. First, alpha 2 -adrenoceptor activation by NE at low concentrations in BN17 cells or by higher concentrations of NE or EPI in NG108 cells does not produce GRK3 up-regulation.
Second, isoproterenol at concentrations that cause similar degrees of beta 2 -adrenoceptor activation as 0.3 µM EPI does not cause up-regulation of GKR3. Finally, up-regulation of GRK3 by EPI in BN17 cells is prevented by beta-adrenoceptor blockade. Hence simultaneous activation of both the alpha 2 -and beta 2 -adrenoceptors was required for GRK3 up-regulation. The mechanisms responsible for GRK3 up-regulation were not studied further as this was not the focus of the present project.
However, in a previous study of alpha 2A -adrenoceptor regulation, it was observed that activation of p42/44 MAP kinase by simultaneous alpha 2 -and beta 2 -adrenoceptor activation was required for GRK3 up-regulation and that inhibition of protein synthesis or GRK3 antisense ODN prevented of the alpha 2B -adrenoceptor, which reduced phosphorylation and eliminated short-term agonistinduced desensitization, was reported to have no effect on long-term agonist-induced receptor down-regulation (Jewell-Motz and Liggett, 1995) . Nevertheless, the results of the present study support a critical role of GRK3 in alpha 2B -adrenoceptor down-regulation.
The important role of the GRKs in alpha 2B -adrenoceptor down-regulation suggested by the present study is in agreement with several recent reports regarding the role of GRKs in the downregulation of other G protein-coupled receptors (GPCRs). For example, the delta opioid receptor has been shown to undergo down-regulation in N18TG2 cells after exposure to etorpine in a GRKdependent manner (Shapira et al., 2001) . Similarly, the human κ-opioid receptor has been shown to undergo down-regulation in a GRK2-dependent manner in CHO cells (Li et al., 2000) . The
This article has not been copyedited and formatted. The final version may differ from this version. expression of the metabotropic glutamate receptor 5 (mGluR5) also was reported to be regulated by GRK2 (Sorensen and Conn, 2003) . This effect of GRK2 requires the presence of a threonine residue (Thr 840) in the carboxyl terminal tail of mGluR5 suggesting a role for GRK-mediated phosphorylation in down-regulating the receptor. Finally, a recent report suggests that GRK2 overexpression reduces the threshold agonist concentration required for down-regulation of the human muscarinic M2 receptor (Tsuga et al., 1998) . Therefore, there is considerable evidence that down-regulation of several GPCRs is regulated by the GRKs.
The role of beta 2 -adrenoceptor mediated GRK3 up-regulation in enabling alpha 2B -adrenoceptor down-regulation by lower EPI concentrations highlights an emerging theme in receptor signal modulation, i.e. heterologous modulation of homologous receptor regulation (Chuang et al., 1996) . Phosphorylation of GPCRs by GRKs requires an agonist-occupied receptor.
For this reason, mechanisms involving GRKs were initially considered as strictly homologous.
However, our results clearly demonstrate that, by contributing to the regulation of GRK3 expression, beta 2 -adrenoceptors heterologously modulate alpha 2B -adrenoceptor down-regulation.
These observations are similar to our previous report where alpha 2A -adrenoceptor regulation by simultaneous alpha 2A -and beta 2 -adrenoceptor activation caused selective GRK3 up-regulation and alpha 2A -adrenoceptor down-regulation at low EPI concentrations (Bawa et al., 2003) . As discussed in a recent review, accumulating evidence suggests that heterologous regulation of GRK expression may play an important role in the heterologous regulation of GPCR signaling (Penela et al., 2003) .
In the context of the present study, it is particularly important to note that this heterologous regulation allows long-term agonist-induced receptor down-regulation and desensitization to occur at significantly lower agonist concentrations than would be required for homologous regulation.
Considering that the alpha 2 -adrenoceptor generally requires micromolar agonist concentrations to produce desensitization compared to the beta 2 -adrenoceptor (Atkinson and Minneman, 1992) , and , 1998) . EPI also produced down-regulation of the alpha 2 -adrenoceptor in these cells by a mechanism that involved a decrease in receptor transcription. However, the changes in alpha 2 -adrenoceptor number observed in the present study appear to have no contribution from changes in cAMP. First, GRK3 antisense, which had no effect on adrenoceptor signaling, abolished EPI-induced alpha 2 -adrenoceptor downregulation. Second, isoproterenol at concentrations that produced beta 2 -adrenoceptor activation similar to that of EPI, and increased cAMP concentrations in BN17 cells, had no effect of alpha 2 -adrenoceptor number. Therefore, the data in the present study are unique in that they emphasize a role for GRK3 expression in this heterologous regulation.
In summary, heterologous up-regulation of GRK3 by simultaneous activation of alpha 2B -and beta 2 -adrenoceptors enables the alpha 2B -adrenoceptor to be down-regulated by significantly lower concentrations of EPI, compared to NE. Future studies will focus on the role of GRKs in alpha 2 -adrenoceptor down-regulation and the influence of cellular levels of GRK expression on the threshold agonist concentrations required for alpha 2 -adrenoceptor down-regulation. 
